Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion

<div>Response to idelalisib-rituximab started on day 0, ibrutinib started in month 6, and reduced-intensity conditioning allo-HSCT was performed in month 8. (a) Absolute lymphocyte count. (b) Platelet count, hemoglobin concentration, and spleen size (measured by CT scan/longest diameter).</div>

Case Reports in Hematology

fig2

Figure 2

Figure 2: Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion 